Sen. Bernie Sanders (I-Vt.), chair of the Senate Health, Education, Labor and Pensions (HELP) Committee, was set to grill Novo Nordisk CEO Lars Jørgensen on Tuesday morning about prices on the drugmaker’s popular weight loss drugs, including Ozempic and Wegovy.

The drugs, which both contain the active ingredient semaglutide, are also used to treat type 2 diabetes.

Sanders launched an investigation into the company’s prices earlier this year, laying out concerns over various price discrepancies between the drugs and between different countries.

The hearing was scheduled to begin at 10 a.m. EDT.

Watch the video replay above.